However, more recent reports suggest that lenalidomide instead binds to CRBN to induce its E3 ligase activity, causing degradation of the Ikaros transcription factors and accounting for the anti-tumor activity in myeloma [24]–[26]. Here, IKZF1 is linked to plasma cell myeloma.